WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2015036898) NOVEL SALTS OF CRIZOTINIB AND THEIR PREPARATION
Latest bibliographic data on file with the International Bureau   

Pub. No.: WO/2015/036898 International Application No.: PCT/IB2014/064224
Publication Date: 19.03.2015 International Filing Date: 03.09.2014
IPC:
A61K 31/4545 (2006.01) ,A61K 31/4465 (2006.01) ,C07D 401/04 (2006.01) ,C07D 401/14 (2006.01)
Applicants: SHILPA MEDICARE LIMITED[IN/IN]; 10/80 Second Floor, Rajendra Gunj, Raichur, Karnataka Raichur 584102, IN
Inventors: UPALLA, Lavkumar; IN
RAMPALLI, Sriram; IN
PATNEEDI, Chantibabu; IN
DANGUDUBIYYAM, Chandrasekhar; IN
CHATURVEDI, Akshaykant; IN
Priority Data:
4026/CHE/201310.09.2013IN
Title (EN) NOVEL SALTS OF CRIZOTINIB AND THEIR PREPARATION
(FR) NOUVEAUX SELS DE CRIZOTINIB ET LEUR PRÉPARATION
Abstract: front page image
(EN) The present invention relates to novel pharmaceutically acceptable substituted aryl acrylic acid addition salts of Crizotinib (I) or its hydrate or solvate thereof. The present invention further relates to processes for preparation of the said substituted aryl acrylic acid addition salts of Crizotinib (I). The present application also provides pharmaceutically acceptable substituted aryl acrylic acid addition salts of Crizotinib (I) or its hydrate or solvate useful as active pharmaceutical ingredient in pharmaceutical composition comprising thereof, possessing anti-cancer activity.
(FR) Cette invention concerne de nouveaux sels d'addition d'acide arylacrylique substitués pharmaceutiquement acceptables de Crizotinib (I) ou de son hydrate ou solvate. Cette invention concerne en outre des procédés de préparation desdits sels d'addition d'acide arylacrylique substitués de Crizotinib (I). Des sels d'addition d'acide arylacrylique substitués pharmaceutiquement acceptables de Crizotinib (I) ou de son hydrate ou solvate utiles à titre de principe pharmaceutique actif dans une composition pharmaceutique les contenant, ayant une activité anticancéreuse sont en outre décrits.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)